Sanofi-Aventis India In Damage Control Mode As Local Press Errs And Says Combiflam Banned, Instead Of Comiflam
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The Indian arm of French multinational Sanofi Aventis went into a speedy damage control mode after several vernacular newspapers incorrectly reported that one of its biggest revenue earners Combiflam (ibuprofen/paracetamol) was banned following an order of the State Drug Authorities in Rajasthan - a state in Western India - under the provisions of the Drugs & Cosmetics Act
You may also be interested in...
Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up
MUMBAI - Outbidding at least six serious rivals, London-headquartered consumer and healthcare products giant Reckitt Benckiser paid a hefty $742 million to clinch the acquisition of India's Paras Pharma - a company that created strong OTC healthcare brands mainly through large-scale mass media campaigns over the last 10 years
Sanofi Aventis Maps Out India R&D Strategy To Broaden Reach Into Untapped Markets
MUMBAI - For the last five years, the Indian affiliate of French drug giant Sanofi Aventis has been working very quietly, assiduously integrating the operations of the two companies that turned into a single entity as part of a mega-deal in 2004 and then drawing up its rollout program under the newly christened identity
Spurious Drugs Issue: Indian Government Proposes Cash Rewards For Informers; Industry Supportive
NEW DELHI - Grappling with increasing incidents of spurious drugs, the Indian health ministry has proposed an incentive scheme for "whistle blowers" who provide credible information and help the government in confiscating fake drugs, cosmetics or medical devices